Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Faron Pharmaceuticals

2.00 EUR

+3.52 %

5,527 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

+3.52 %
-14.71 %
-6.54 %
-26.61 %
-21.26 %
-10.71 %
-52.49 %
-38.08 %
-42.53 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
237.13M EUR
Turnover
872.16K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
24.10.2025
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.10.2025

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.3.
2026

Annual report '25

30.3.
2026

General meeting '26

26.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Faron ESMO 2025
Webcast

Faron ESMO 2025

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insights.

Faron Pharmaceuticals
Forum discussions
It’s hard for me to understand how anyone can consider selling a stock as treason, or owning a publicly traded stock as some kind of alliance with the company or other investors. And I don’t know what Eka means by transferring to a “long-term portfolio” in Faron’s case; as I understand...
4 hours ago
by micoat
27
This is a good point, because an investment can also go completely wrong if the partnership terms are too poor. Earlier on the forum, the motto was, “Faron is a Phase II company, Faron is a Phase II company, Faron is a Phase II company”, which was the response to warnings that Phase...
9 hours ago
by Pohjolan Eka
25
Faron on LinkedIn reviews ASH. Shares praise for itself, but this time also for others. Now it’s time to be a nice friend with all pharmas. Theme of response depth: ”Depth matters: Composite CR (cCR) and MRD negativity are becoming critical metrics for durability, alongside SCT bridging...
6 hours ago
by Vino Pino
15
In the Finprove study, the included drugs appear to be approved drugs in use, it’s great that Bex is included in that study even though it’s still in the research phase. AI invest’s view on Faron Ainvest Faron's Strategic Financing Moves and Implications for Bexmarilimab's Path to...
4 hours ago
by Koodinikkari
12
I would add to this list that many investors in Faron seem to have entered into an eternal marriage with the company and its management. No event can make the most committed investors change their opinion of the company as an investment, and those who exit the stock are somewhat ...
6 hours ago
9
I’m wondering what exactly is the basis of these other thoughts “spoken aloud” regarding the faron stock - aren’t these basic theses and inherently things related to biotech investing that one could ponder on their own channel? faron seems, regarding stock-specific investing, to ...
7 hours ago
by Pekka
8
Without attempting to answer the whole question, one partial truth is that there are 1.4 billion Chinese people, and they have cancers proportionally, and the population is only aging. More in the digestive tract, fewer skin cancers. A couple of Chinese articles discussed Clever ...
11 hours ago
by Vino Pino
7
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.